Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(22%)
Results Posted
67%(2 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
4
44%
Ph phase_2
3
33%
Ph phase_4
2
22%

Phase Distribution

0

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
4(44.4%)
Phase 4Post-market surveillance
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(3)
Terminated(2)
Other(2)

Detailed Status

Completed3
unknown2
Recruiting2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (33.3%)
Phase 34 (44.4%)
Phase 42 (22.2%)

Trials by Status

withdrawn111%
completed333%
unknown222%
recruiting222%
terminated111%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_3

Randomised Evaluation of COVID-19 Therapy

NCT04381936
recruitingphase_4

Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

NCT04589299
withdrawnphase_3

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

NCT03492710
completedphase_2

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
completedphase_2

Immunotherapy and Paraneoplastic Neurological Syndromes

NCT02343211
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04381936Phase 3

Randomised Evaluation of COVID-19 Therapy

Recruiting
NCT04589299Phase 4

Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)

Recruiting
NCT03492710Phase 3

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

Withdrawn
NCT01561053Phase 2

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Completed
NCT02343211Phase 2

Immunotherapy and Paraneoplastic Neurological Syndromes

Completed
NCT01895127Phase 2

Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation

Terminated
NCT03200561Phase 3

A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)

Unknown
NCT02990403Phase 4

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

Unknown
NCT00000117Phase 3

Intravenous Immunoglobulin Therapy in Optic Neuritis

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9